哌柏西利联合来曲唑治疗二线化疗进展后激素受体阳性高级别浆液性或子宫内膜样卵巢、输卵管或腹膜癌女性的II期试验(LACOG 1018)
LACOG 1018是一项单臂多中心II期试验,评估来曲唑2.5 mg/日持续联合哌柏西利125 mg/日(28天周期中用21天)用于至少接受过两线化疗(含一种铂类方案)且既往化疗进展的组织学证实卵巢高级别浆液性癌或高级别子宫内膜样癌、输卵管或腹膜癌患者。41例合格患者中,12周无进展生存率为63.4%(95%CI 46.8至76.1),中位无进展生存4.2个月(95%CI 2.7至5.5),中位总生存13.4个月(95%CI 10.4至20.1)。
要点
- 12周无进展生存率为63.4%(95%CI 46.8至76.1),中位无进展生存4.2个月(95%CI 2.7至5.5)。
- 客观缓解率7.7%(3例部分缓解),疾病控制率71.8%。
- 任何级别治疗相关不良事件率95.1%,3-4级51.2%;3-4级中性粒细胞减少17例(41.5%),发热性中性粒细胞减少1例(2.4%)。
核心结论
- 哌柏西利联合来曲唑具有有利的毒性特征,在复发性激素受体阳性高级别卵巢癌中似乎具有临床活性。
研究设计与样本
- LACOG 1018是一项II期、单臂、多中心试验,评估来曲唑2.5 mg/日持续联合哌柏西利125 mg/日(28天周期中用21天)的疗效。
- 纳入组织学证实的卵巢高级别浆液性癌或高级别子宫内膜样癌、输卵管或腹膜癌患者,至少接受过两线化疗(含一种铂类方案)且既往化疗进展。
- 患者经中心确认激素阳性——雌激素或孕激素(免疫组化>10%)。
- 主要终点为研究者按RECIST 1.1评估的12周无进展生存率。
- 共纳入41例合格患者(2020年2月至2022年1月),中位年龄61岁(范围43-83)。
主要发现
- 12周无进展生存率为63.4%(95%CI 46.8至76.1)。
- 中位无进展生存4.2个月(95%CI 2.7至5.5),中位总生存13.4个月(95%CI 10.4至20.1)。
- 客观缓解率7.7%(3例部分缓解),疾病控制率71.8%。
- 任何级别和3-4级治疗相关不良事件率分别为95.1%和51.2%。
- 3-4级中性粒细胞减少报告于17例患者(41.5%),发热性中性粒细胞减少1例(2.4%)。
关键数值与推荐
- 激素阳性定义为雌激素或孕激素免疫组化>10%。
- 来曲唑剂量为2.5 mg/日持续给药,哌柏西利剂量为125 mg/日,28天周期中用21天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment options for patients with ovarian high-grade serous carcinoma (HGSC) and high-grade endometrioid carcinoma (HGEC) who progress after receiving chemotherapy are limited. Considering that over 80 % of those patients express ER and/or PR, we aimed to evaluate the effectiveness of endocrine therapy combined with CDK inhibitors in this population. METHODS: LACOG 1018, a phase II, single-arm, multicenter trial assessed the efficacy of letrozole 2.5 mg/day continuously plus palbociclib 125 mg/day for 21 days in 28-day cycles in patients with histologically proven ovarian HGSC or HGEC, fallopian tube or peritoneal cancer who had received at least two lines of chemotherapy (including one platinum-based regimen) and progressed on prior chemotherapy. Patients had centrally confirmed hormone positivity - estrogen or progesterone (>10 % by immunohistochemistry). The primary endpoint was investigator-assessed progression-free survival rate at 12 weeks (PFS-week12) by RECIST 1.1. RESULTS: 41 eligible patients were included (February/2020 to January/2022). The median age was 61 years (range 43-83). The PFS-week12 rate was 63.4 % (95 % CI, 46.8 to 76.1), median PFS 4.2 months (95 % CI, 2.7 to 5.5), and median overall survival 13.4 months (95 % CI, 10.4 to 20.1). The objective response rate was 7.7 % (3 partial responses) and the disease control rate 71.8 %. Treatment-related adverse event rates of any grade and grade 3-4 were 95.1 % and 51.2 %, respectively. Grade 3-4 neutropenia was reported in 17 patients (41.5 %), and febrile neutropenia in 1 (2.4 %). CONCLUSIONS: The combination of Palbociclib plus letrozole has a favorable toxicity profile and appears to have clinical activity in recurrent hormone receptor-positive high-grade ovarian cancer.
引用
- Damian FB, De Melo AC, Dal Molin GZ, et al. A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018). Gynecol Oncol. 2025. PMID: 40505182. doi:10.1016/j.ygyno.2025.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。